US 11,969,412 B2
Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza
Adrian Huw Davies, London (GB); Pui-Man Choy, London (GB); Vinay Saunders, London (GB); Basma Bahsoun, London (GB); Surender Vashist, London (GB); Neil Edward Torbett, London (GB); and Paul Andrew Whittaker, London (GB)
Assigned to Poolbeg Pharma (UK) Limited, London (GB)
Filed by Poolbeg Pharma (UK) Limited, London (GB)
Filed on Sep. 23, 2022, as Appl. No. 17/951,651.
Application 17/951,651 is a continuation of application No. 16/957,063, granted, now 11,590,112, previously published as PCT/GB2018/053732, filed on Dec. 20, 2018.
Claims priority of application No. 1721793 (GB), filed on Dec. 22, 2017.
Prior Publication US 2023/0094776 A1, Mar. 30, 2023
Int. Cl. A61K 31/437 (2006.01); A61P 31/16 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/437 (2013.01) [A61P 31/16 (2018.01); A61K 45/06 (2013.01)] 16 Claims
 
1. A method of treating hypercytokinemia in a human or animal patient in need thereof, or a prophylactic method of treating a human or animal patient at risk of developing hypercytokinemia after an immune response has been triggered, comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAP kinase inhibitor, wherein:
the p38 MAP kinase inhibitor is of Formula I or a pharmaceutically acceptable salt or solvate thereof:

OG Complex Work Unit Chemistry
wherein R is C1-3 alkyl, optionally substituted by one or more halo, NR1R2 hydroxy, and R1 and R2 are independently H, halo or C1-3 alkyl, optionally substituted by one or more F.